Acceleron Pharma Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 312

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $11.5B

  • Investors
  • 1

Acceleron Pharma General Information

Description

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 128 Sidney Street
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 128 Sidney Street
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Acceleron Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
19. Merger/Acquisition 19-Nov-2021 $11.5B Completed Generating Revenue
18. 2PO 06-Jan-2016 Completed Generating Revenue
17. Secondary Transaction - Open Market Completed Generating Revenue
16. PIPE 24-Aug-2015 Completed Generating Revenue
15. PIPE 24-Sep-2013 Completed Clinical Trials - Phase 2
14. IPO 19-Sep-2013 Completed Clinical Trials - Phase 2
13. Debt - General 01-Jun-2012 Completed Clinical Trials - Phase 2
12. Later Stage VC (Series F) 23-Dec-2011 Completed Clinical Trials - Phase 2
11. Grant 06-Jan-2011 $1.5M $137M Completed Clinical Trials - Phase 2
10. Later Stage VC (Series E) 18-Jun-2010 $8.35M $137M Completed Clinical Trials - Phase 2
To view Acceleron Pharma’s complete valuation and funding history, request access »

Acceleron Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series F
Series E
Series D1
Series D
Series C1
Series C
Series B 16,944,378 $0.001000 8% $1.85 $1.85 1x $1.85 16.6%
Series A 26,069,980 $0.001000 8% $1 $1 1x $1 25.54%
To view Acceleron Pharma’s complete cap table history, request access »

Acceleron Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therap
Drug Discovery
Cambridge, MA
312 As of 2020

Newark, CA
 

Loos, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Acceleron Pharma Competitors (74)

One of Acceleron Pharma’s 74 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Protagonist Therapeutics Formerly VC-backed Newark, CA
Genfit Formerly VC-backed Loos, France
Verve Therapeutics Formerly VC-backed Boston, MA
Idorsia Pharmaceuticals Corporation Allschwil, Switzerland
Bicycle Therapeutics Formerly VC-backed Cambridge, United Kingdom
You’re viewing 5 of 74 competitors. Get the full list »

Acceleron Pharma Patents

Acceleron Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260132207-A1 Activin type 2 receptor binding proteins and uses thereof Pending 31-Jul-2025
US-20230398181-A1 Treatments for complications associated with chronic liver disease Pending 08-Jun-2022
US-20230398182-A1 Treatments for hermansky-pudlak syndrome Pending 08-Jun-2022
EP-4387647-A2 Compositions and methods for treating renal diseases or conditions Pending 16-Aug-2021
EP-4387647-A4 Compositions and methods for treating renal diseases or conditions Pending 16-Aug-2021 A61K38/179
To view Acceleron Pharma’s complete patent history, request access »

Acceleron Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acceleron Pharma Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advanced Technology Ventures Venture Capital Minority
Alkermes Corporation Minority
Avalon Ventures Venture Capital Minority
Bessemer Venture Partners Venture Capital Minority
Bock Family Ventures Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Acceleron Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Acceleron Pharma’s complete esg history, request access »

Acceleron Pharma FAQs

  • When was Acceleron Pharma founded?

    Acceleron Pharma was founded in 2003.

  • Where is Acceleron Pharma headquartered?

    Acceleron Pharma is headquartered in Cambridge, MA.

  • What is the size of Acceleron Pharma?

    Acceleron Pharma has 312 total employees.

  • What industry is Acceleron Pharma in?

    Acceleron Pharma’s primary industry is Drug Discovery.

  • Is Acceleron Pharma a private or public company?

    Acceleron Pharma is a Private company.

  • What is the current valuation of Acceleron Pharma?

    The current valuation of Acceleron Pharma is .

  • What is Acceleron Pharma’s current revenue?

    The current revenue for Acceleron Pharma is .

  • How much funding has Acceleron Pharma raised over time?

    Acceleron Pharma has raised $425M.

  • Who are Acceleron Pharma’s investors?

    Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Venture Partners, and Bock Family Ventures are 5 of 17 investors who have invested in Acceleron Pharma.

  • Who are Acceleron Pharma’s competitors?

    Protagonist Therapeutics, Genfit, Verve Therapeutics, Idorsia Pharmaceuticals, and Bicycle Therapeutics are some of the 74 competitors of Acceleron Pharma.

  • When was Acceleron Pharma acquired?

    Acceleron Pharma was acquired on 19-Nov-2021.

  • Who acquired Acceleron Pharma?

    Acceleron Pharma was acquired by Merck & Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process